CHRS - Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? | Benzinga
Coherus BioSciences Inc (NASDAQ:CHRS) shares are trading higher after the company agreed to divest its Cimerli ophthalmology franchise to Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) for $170 million plus an additional amount for inventory.
This divestiture aligns with Coherus’ strategic focus on oncology, and includes Coherus’ Cimerli biologics license application, ophthalmology sales and select field reimbursement teams, Cimerli product inventory on hand, and access to proprietary commercial software.
“Since entering ...